Agios Pharmaceuticals: chief medical officer Sarah Gheuens exercised 1,989 shares

What happened

• Sarah Gheuens, chief medical officer, exercised options for a total of 1,989 shares and sold those 1,989 shares on the open market.
• Exercises: 1,489 shares on Oct 21, 2026 at $25.01 for $37,240; 500 shares on Oct 22, 2026 at $25.01 for $12,505 (total exercise cost $49,745).
• Sales: 1,489 shares sold on Oct 21, 2026 at a weighted average price of $37.53 for $55,882; 500 shares sold on Oct 22, 2026 at a weighted average price of $37.52 for $18,760 (total sale proceeds $74,642).

Key details

• Transaction dates and prices:
  • Oct 21, 2026: exercised 1,489 shares @ $25.01 (acquired) = $37,240; sold 1,489 shares @ weighted avg $37.53 = $55,882.
  • Oct 22, 2026: exercised 500 shares @ $25.01 (acquired) = $12,505; sold 500 shares @ weighted avg $37.52 = $18,760.
• Shares owned after the transactions: not stated in the filing.
• Relevant footnotes from the filing:
  • F1: the Oct 21 sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • F2: the reported sale prices are weighted averages; sales ranged $37.52 to $37.55 and the filer can provide per-price counts on request.
  • F3: the option was granted Mar 1, 2023; underlying shares vest 25% on Mar 1, 2024, with the remaining 75% vesting in 36 equal monthly installments.
• Filing date: filed on Oct 23, 2026 (no late filing indicated in the report).

Why it may matter

• The filing shows options were exercised and the same shares were sold on Oct 21-22, 2026, i.e., the shares were sold soon after exercise (cashless exercise).
• A filing does not show why the insider traded or why the company acted.